DK3332006T3 - Hidtil ukendte anti-PD-L1-antistoffer - Google Patents
Hidtil ukendte anti-PD-L1-antistoffer Download PDFInfo
- Publication number
- DK3332006T3 DK3332006T3 DK16832346.7T DK16832346T DK3332006T3 DK 3332006 T3 DK3332006 T3 DK 3332006T3 DK 16832346 T DK16832346 T DK 16832346T DK 3332006 T3 DK3332006 T3 DK 3332006T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- novel anti
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/086216 WO2017020291A1 (en) | 2015-08-06 | 2015-08-06 | Novel anti-pd-l1 antibodies |
PCT/CN2016/093560 WO2017020858A1 (en) | 2015-08-06 | 2016-08-05 | Novel anti-pd-l1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3332006T3 true DK3332006T3 (da) | 2024-01-02 |
Family
ID=57942317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16832346.7T DK3332006T3 (da) | 2015-08-06 | 2016-08-05 | Hidtil ukendte anti-PD-L1-antistoffer |
Country Status (22)
Country | Link |
---|---|
US (2) | US10981995B2 (da) |
EP (1) | EP3332006B1 (da) |
JP (2) | JP7066614B2 (da) |
KR (1) | KR20180037222A (da) |
AU (1) | AU2016301718B2 (da) |
BR (1) | BR112018002428A2 (da) |
CA (1) | CA2993272A1 (da) |
DK (1) | DK3332006T3 (da) |
ES (1) | ES2966890T3 (da) |
FI (1) | FI3332006T3 (da) |
HK (1) | HK1257164A1 (da) |
HR (1) | HRP20231664T1 (da) |
HU (1) | HUE064563T2 (da) |
IL (1) | IL256803B2 (da) |
LT (1) | LT3332006T (da) |
MX (1) | MX2018001530A (da) |
PT (1) | PT3332006T (da) |
RS (1) | RS64977B1 (da) |
RU (1) | RU2736151C2 (da) |
SA (1) | SA518390862B1 (da) |
SI (1) | SI3332006T1 (da) |
WO (2) | WO2017020291A1 (da) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Antibodies against PD-L1 |
KR20230044038A (ko) | 2016-08-09 | 2023-03-31 | 키맵 리미티드 | 항-icos 항체 |
JP7258747B2 (ja) | 2016-10-28 | 2023-04-17 | ブリストル-マイヤーズ スクイブ カンパニー | 抗pd-1抗体を用いた尿路上皮癌の処置方法 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
CN110494450A (zh) | 2017-03-31 | 2019-11-22 | 百时美施贵宝公司 | ***的方法 |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
RU2665790C1 (ru) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
HRP20231457T1 (hr) | 2017-05-30 | 2024-05-10 | Bristol-Myers Squibb Company | Liječenje lag-3-pozitivnih tumora |
WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
JP2020522508A (ja) * | 2017-06-01 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体を用いる腫瘍の治療方法 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
CA3081748A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2019094265A1 (en) * | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Pd1 polypeptide binding molecules |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
CN111542543B (zh) * | 2017-12-28 | 2023-12-22 | 南京传奇生物科技有限公司 | 针对pd-l1的抗体及其变体 |
KR20200109339A (ko) | 2018-01-16 | 2020-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체를 사용하여 암을 치료하는 방법 |
AU2019210332A1 (en) | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
AU2019209435A1 (en) | 2018-01-22 | 2020-09-17 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
CN117442717A (zh) * | 2018-06-01 | 2024-01-26 | 大有华夏生物医药集团有限公司 | 治疗疾病或病况的组合物及其用途 |
WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
BR112021000511A2 (pt) | 2018-07-26 | 2021-04-06 | Bristol-Myers Squibb Company | Terapia de combinação de lag-3 para o tratamento de câncer |
JP2021533124A (ja) | 2018-07-31 | 2021-12-02 | アセンテージ ファーマ(スーチョウ)カンパニー,リミティド | Iap阻害剤及び免疫チェックポイント分子の調節剤の組合せによる癌を治療するための方法 |
CN116063519A (zh) * | 2018-08-20 | 2023-05-05 | 北京强新生物科技有限公司 | 新型癌症免疫治疗抗体组合物 |
JP2022512642A (ja) | 2018-10-09 | 2022-02-07 | ブリストル-マイヤーズ スクイブ カンパニー | がんを治療するための抗MerTK抗体 |
EP3866850A1 (en) | 2018-10-19 | 2021-08-25 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
CN112912403A (zh) | 2018-10-23 | 2021-06-04 | 百时美施贵宝公司 | ***的方法 |
CA3119838A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
EP3902563A4 (en) * | 2018-12-27 | 2022-12-28 | Gigagen, Inc. | ANTI-PD-L1 BINDING PROTEINS AND METHODS OF USE THEREOF |
EP3946625A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
CN114206926B (zh) * | 2019-06-10 | 2022-06-17 | 山东博安生物技术股份有限公司 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
SG11202103221QA (en) * | 2019-08-29 | 2021-04-29 | Remegen Co Ltd | Anti pd-l1 antibody and use thereof |
AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
JP2022549337A (ja) | 2019-09-25 | 2022-11-24 | ブリストル-マイヤーズ スクイブ カンパニー | がん療法のための複合バイオマーカー |
EP4034569A4 (en) * | 2019-09-26 | 2023-11-01 | Wuxi Biologics Ireland Limited | NOVEL BISPECIFIC ANTI-PD-L1/ANTI-LAG-3 ANTIBODY AND ITS USES |
WO2021092044A1 (en) | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092380A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
AU2020383580A1 (en) * | 2019-11-11 | 2022-05-12 | Cstone Pharmaceuticals | Pharmaceutical combination and use thereof |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
MX2022006932A (es) | 2019-12-19 | 2022-07-11 | Bristol Myers Squibb Co | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. |
WO2021152548A1 (en) | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
KR20220151195A (ko) | 2020-03-06 | 2022-11-14 | 오엔에이 테라퓨틱스 에스.엘. | 항-cd36 항체 및 암을 치료하기 위한 이의 용도 |
US20230119066A1 (en) | 2020-03-23 | 2023-04-20 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
WO2021207242A2 (en) * | 2020-04-07 | 2021-10-14 | Fred Hutchinson Cancer Research Center | Anti-mesothelin antigen-binding molecules and uses thereof |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
WO2022031882A1 (en) * | 2020-08-06 | 2022-02-10 | Stelexis Therapeutics, Llc | Il-8 antibodies and methods of use thereof |
JP2023540255A (ja) | 2020-08-28 | 2023-09-22 | ブリストル-マイヤーズ スクイブ カンパニー | 肝細胞癌のためのlag-3アンタゴニスト療法 |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022076318A1 (en) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | 肺がんのためのlag-3アンタゴニスト療法 |
IL302346A (en) | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an AHR inhibitor with a PDX inhibitor or doxorubicin |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル-マイヤーズ スクイブ カンパニー | Pd1/pd-l1抗体の皮下投与 |
EP4267105A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
AU2022320051A1 (en) | 2021-07-30 | 2024-01-25 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202321296A (zh) * | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2023230624A2 (en) * | 2022-05-27 | 2023-11-30 | Taipei Medical University | Epha2-targeting antibodies and their applications in cancer treatment |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
JP2024013645A (ja) | 2022-07-20 | 2024-02-01 | セイコーエプソン株式会社 | 微細化装置 |
EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6048911A (en) | 1997-12-12 | 2000-04-11 | Borden Chemical, Inc. | Coated optical fibers |
AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
CN101104540A (zh) * | 2006-07-13 | 2008-01-16 | 康那香企业股份有限公司 | 污水处理***及其方法 |
NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
PT2336329E (pt) | 2007-06-01 | 2012-12-24 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos |
WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
KR20210060670A (ko) * | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
SI3279215T1 (sl) | 2009-11-24 | 2020-07-31 | Medimmune Limited | Usmerjena vezavna sredstva proti B7-H1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2013164404A1 (en) * | 2012-05-02 | 2013-11-07 | Spiber Technologies Ab | Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands |
KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
US9626778B2 (en) | 2012-06-01 | 2017-04-18 | The Johns Hopkins University | Information propagation in prior-image-based reconstruction |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
AU2014214843A1 (en) | 2013-02-07 | 2015-05-21 | Immunomedics, Inc. | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
CA2923499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-pd-l1 antibodies for treating non-small cell lung carcinoma (nsclc) |
SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
AU2015213988B2 (en) * | 2014-02-10 | 2019-07-11 | Merck Patent Gmbh | Targeted TGFbeta inhibition |
RU2017108173A (ru) | 2014-08-14 | 2018-09-17 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 |
-
2015
- 2015-08-06 WO PCT/CN2015/086216 patent/WO2017020291A1/en active Application Filing
-
2016
- 2016-08-05 IL IL256803A patent/IL256803B2/en unknown
- 2016-08-05 AU AU2016301718A patent/AU2016301718B2/en active Active
- 2016-08-05 EP EP16832346.7A patent/EP3332006B1/en active Active
- 2016-08-05 WO PCT/CN2016/093560 patent/WO2017020858A1/en active Application Filing
- 2016-08-05 CA CA2993272A patent/CA2993272A1/en active Pending
- 2016-08-05 SI SI201631777T patent/SI3332006T1/sl unknown
- 2016-08-05 PT PT168323467T patent/PT3332006T/pt unknown
- 2016-08-05 FI FIEP16832346.7T patent/FI3332006T3/fi active
- 2016-08-05 ES ES16832346T patent/ES2966890T3/es active Active
- 2016-08-05 US US15/749,783 patent/US10981995B2/en active Active
- 2016-08-05 HR HRP20231664TT patent/HRP20231664T1/hr unknown
- 2016-08-05 RU RU2018107658A patent/RU2736151C2/ru active
- 2016-08-05 JP JP2018526289A patent/JP7066614B2/ja active Active
- 2016-08-05 KR KR1020187005942A patent/KR20180037222A/ko not_active Application Discontinuation
- 2016-08-05 MX MX2018001530A patent/MX2018001530A/es unknown
- 2016-08-05 HU HUE16832346A patent/HUE064563T2/hu unknown
- 2016-08-05 DK DK16832346.7T patent/DK3332006T3/da active
- 2016-08-05 LT LTEPPCT/CN2016/093560T patent/LT3332006T/lt unknown
- 2016-08-05 RS RS20231228A patent/RS64977B1/sr unknown
- 2016-08-05 BR BR112018002428A patent/BR112018002428A2/pt active Search and Examination
-
2018
- 2018-02-01 SA SA518390862A patent/SA518390862B1/ar unknown
- 2018-12-06 HK HK18115668.9A patent/HK1257164A1/zh unknown
-
2021
- 2021-03-12 US US17/200,374 patent/US20210269528A1/en active Pending
-
2022
- 2022-04-27 JP JP2022072902A patent/JP2022115897A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3332006B1 (en) | 2023-10-11 |
SA518390862B1 (ar) | 2021-12-21 |
ES2966890T3 (es) | 2024-04-24 |
EP3332006A4 (en) | 2019-01-09 |
RU2736151C2 (ru) | 2020-11-12 |
JP2022115897A (ja) | 2022-08-09 |
RU2018107658A (ru) | 2019-09-09 |
IL256803A (en) | 2018-03-29 |
JP7066614B2 (ja) | 2022-05-13 |
IL256803B2 (en) | 2023-03-01 |
HK1257164A1 (zh) | 2019-10-18 |
SI3332006T1 (sl) | 2024-02-29 |
KR20180037222A (ko) | 2018-04-11 |
CA2993272A1 (en) | 2017-02-09 |
FI3332006T3 (fi) | 2023-12-05 |
US10981995B2 (en) | 2021-04-20 |
AU2016301718B2 (en) | 2022-05-12 |
JP2018527949A (ja) | 2018-09-27 |
HUE064563T2 (hu) | 2024-04-28 |
WO2017020291A1 (en) | 2017-02-09 |
RU2018107658A3 (da) | 2020-02-10 |
IL256803B (en) | 2022-11-01 |
PT3332006T (pt) | 2024-01-09 |
LT3332006T (lt) | 2023-12-27 |
EP3332006A1 (en) | 2018-06-13 |
US20200140554A1 (en) | 2020-05-07 |
AU2016301718A1 (en) | 2018-01-18 |
RS64977B1 (sr) | 2024-01-31 |
US20210269528A1 (en) | 2021-09-02 |
MX2018001530A (es) | 2018-08-01 |
HRP20231664T1 (hr) | 2024-03-15 |
BR112018002428A2 (pt) | 2018-09-18 |
WO2017020858A1 (en) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
ZA201900353B (en) | Anti-pd-l1 antibodies | |
IL255727A (en) | Novel anti-pd-l1 antibodies | |
HK1246324A1 (zh) | 抗pd-l1抗體 | |
CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
BR112017002234A2 (pt) | anticorpos anti-pd-l1 | |
KR102355950B9 (ko) | Tigit에 대한 항체 | |
DK3411410T3 (da) | Pd-1-antistoffer | |
DK3334824T3 (da) | Pd-1-antistoffer | |
BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
MA53297A (fr) | Anticorps anti-icos | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
DK3126395T3 (da) | Multispecifikke antistoffer | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3215530T3 (da) | Forbedrede il-6 antistoffer | |
DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof | |
DK3116908T3 (da) | Humaniserede kir3dl2-antistoffer |